Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 9/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | PADI6 | Q6TGC4 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.41 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.41 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28542235 | 0.87 | TGM2 (0.51) | TGM2MCHR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28542237 | 0.87 | TGM2 (0.51) | TGM2MCHR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15921797 | 0.85 | NPY4R (0.45) | TGM2MCHR1SCN5ASCN2A | |
| SCHEMBL290267 | 0.84 | NPC1 (0.50) | TGM2ALDH1A1ITGB3 | |
| SCHEMBL290268 | 0.84 | NPC1 (0.50) | TGM2ALDH1A1ITGB3 | |
| SCHEMBL14861047 | 0.83 | SCN5A (0.44) | TGM2MCHR1SCN5ASCN2AALDH1A1 | |
| SCHEMBL10652468 | 0.81 | GRIN1 (0.48) | GRIN1GRIN2APADI6PDE4APDE4B | |
| Naphthalene SCHEMBL28216957 | 0.81 | C3AR1 (0.49) | TGM2GRIN1GRIN2APADI6PDE4A | |
| SCHEMBL6553039 | 0.81 | TGM2 (0.45) | TGM2GRIN1GRIN2APADI6PDE4A | |
| SCHEMBL27410099 | 0.81 | TGM2 (0.45) | TGM2GRIN1GRIN2APADI6PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710033-A1 | NUCLEAR-TARGETED DNA REPAIR ENZYMES AND METHODS OF USE | Oregon Health & Science University (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200283745-A1 | NUCLEAR-TARGETED DNA REPAIR ENZYMES AND METHODS OF USE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-2205623-B1 | PROTECTIVE SKIN CARE TETRAPEPTIDES | HELIX BIOMEDIX INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2512498-B1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8597902-B2 | Peptide protection against ultraviolet light toxicity | HELIX BIOMEDIX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2512498-A2 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | Helix Biomedix Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120225023-A1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2011063090-A2 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| EP-2205623-A1 | PROTECTIVE SKIN CARE TETRAPEPTIDES | Helix Biomedix Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090142280-A1 | Protective skin care peptides | HELIX BIOMEDIX INC. | 2009-06-04 | — | — | US | disclosed |
| WO-2009058244-A1 | PROTECTIVE SKIN CARE TETRAPEPTIDES | HELIX BIOMEDIX INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283745-A1 | NUCLEAR-TARGETED DNA REPAIR ENZYMES AND METHODS OF USE | DCLRE1A, UNG, DCLRE1B | TGM2 965/4885MCHR1 3840/4885SCN5A 4754/4885 |
| US-20120225023-A1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | CHEK2, CHEK1, DDB1 | TGM2 461/4885MCHR1 2406/4885SCN5A 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.